OpportunityTitle: AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following: The eligibility to apply in response to this limited competition FOA is limited to the current AMC Group Chair recipient institution (U01CA121947).
Description: Purpose. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The award will provide subcontracts for a coordinating center, core sites, affiliate sites, network laboratories and a statistical center. Sites will receive patient care costs on a capitation basis and for laboratory correlative studies, clinical pharmacology and international studies. The group will have at least four scientific disease-oriented working groups (WG) - KS, lymphoma, HPV-associated cancers, and non-AIDS-Defining Cancers (NADCs) Working Groups . Mechanism of Support. This FOA will use the NIH U01 cooperative agreement award mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that $ 4.68 million for year one will be available for this initiative, and one application is expected to be awarded.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;